Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLIPPER Study
2024-516132-10-00Phase 2Completed
- Sponsor
- GEICAM
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Fulvestrant + placebo with Fulvestrant + palbociclib (2 arms). Primary endpoint: Rate of patients free of progression at 1 year. Started Oct 2024; status: completed.
02
Drugs
fulvestrantpalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516132-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516132-10-00.